Abstracts tagged "Checkpoint Inhibitors and registry"

Abstract Number: 1905 • 2019 ACR/ARP Annual Meeting
Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)
Manuel Ramos-Casals ¹, Alexandre Maria ², Maria E. Suárez-Almazor ³, Olivier Lambotte ⁴, Benjamin A. Fisher ⁵, Gabriela Hernandez-Molina ⁶, Philippe Guilpain ², Xerxes Pundole ³, Soledad Retamozo⁷, Alejandra Flores-Chávez ⁸, Chiara Baldini ⁹, Clifton Bingham ¹⁰, Pilar Brito-Zerón ¹¹, Jacques-Eric Gottenberg ¹², Marie Kostine ¹³, Timothy R.D. Radstake ¹⁴, Thierry Schaeverbeke ¹⁵, Hendrik Schulze-Koops ¹⁶, Leonard Calabrese ¹⁷, Munther A Khamashta ¹⁸ and Xavier Mariette ¹⁹, ¹Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ²Department of Internal Medicine, Multi-Organic Diseases, Local Referral Center for Autoimmune Diseases, Saint Eloi Hospital- Montpellier-1 University, Montpellier Cedex 5, France, Montpellier, France, ³Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX, ⁴APHP Médecine Interne/Immunologie Clinique, Hôpital Bicêtre, Paris, France. Université Paris Sud 11 – INSERM U1184 - CEA, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Paris, France, ⁵Institute of Inflammation and Ageing, University of Birmingham; and National Institute of Health Research Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷Instituto De Investigaciones En Ciencias De La Salud, Univ. Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina., Cordoba, Argentina, ⁸Department of Autoimmune Diseases, ICMiD, Barcelona, Spain., Barcelona, Spain, ⁹Rheumatology Unit, University of Pisa, Italy., Pisa, Italy, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic. Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain., Barcelona, Spain, ¹²Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ¹⁴Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ¹⁵FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ¹⁶Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany., Munich, Germany, ¹⁷Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH, ¹⁸King's College London School of Medicine, London, United Kingdom, ¹⁹Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: To analyse the worldwide occurrence of sicca/Sjögren (SjS) syndrome associated with the use of immune checkpoint inhibitors (ICI) in patients with cancer.Methods: The ImmunoCancer…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].